Kyndryl Flat Revenue, Cautious Outlook Test Turnaround Thesis

What happened

Kyndryl reported flat full-year fiscal 2026 revenue and a cautious FY27 outlook, as longer sales cycles and shifts in IBM-related customer buying continue to pressure top-line growth, while management highlighted margin expansion, cash generation, and strength in consulting and hyperscaler services. The DeepValue report, rating the stock a Potential Buy at ~$27, sees value at ~11x trailing EPS and ~5.5x EV/EBITDA, supported by $34B+ in backlog and record signings, but acknowledges significant execution risk after recent revenue misses and lumpy cash generation. H1 FY26 free cash flow of only $22M underscores volatility, and the modest equity cushion against $2.9B debt limits downside protection if growth stalls. The thesis depends on converting strong signings into modest revenue growth and sustained margin expansion over the next 6-18 months; failure to meet FY26 guidance would validate the bear case. The cautious Q4 update pushes the revenue inflection further out, making upcoming quarterly results critical for credibility, but the depressed valuation already discounts much of the uncertainty.

Implication

At current depressed multiples, the risk/reward is favorable if Kyndryl delivers on FY26 guidance and progresses toward FY28 targets, offering mid-teens annualized returns from earnings growth and multiple expansion.

Thesis delta

The Q4 update reinforces the existing thesis but highlights that the revenue inflection is delayed, increasing the importance of FY26 results. The bear case probability has slightly risen given the cautious FY27 outlook, but the base case still expects 1-2% constant currency growth and ~$550M FCF in FY26. The market's skepticism is already priced in, so the thesis remains intact with a tighter timeline for execution.